Status:
UNKNOWN
Efficacy of Topical Pimecrolimus in the Treatment of Pityriasis Alba
Lead Sponsor:
St Joseph University, Beirut, Lebanon
Conditions:
Pityriasis Alba
Eligibility:
All Genders
2+ years
Phase:
PHASE2
PHASE3
Brief Summary
Pityriasis alba (PA) is a common benign skin disorder, that usually affects children and adolescents of darker phototypes. A history of atopic dermatitis is a well-known risk factor, and PA may be a m...
Detailed Description
Background and Rationale: Pityriasis alba (PA) is a common benign skin disorder, that usually affects children and adolescents of darker phototypes. PA usually manifests as erythematous lesions follo...
Eligibility Criteria
Inclusion
- Pityriasis alba Patients confirmed by a board certified dermatologist
- Age over 2 years
- Written informed consent signed by the patients or the legal guardians of patients younger than 18 years in the native language (Arabic)
Exclusion
- Other concomitant dermatosis (except atopic dermatitis)
- Use of topical steroids, or topical agents other than emollients and sunscreen, in the last 4 weeks
- Known allergy to pimecrolimus
- Pregnant and nursing women
Key Trial Info
Start Date :
March 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2021
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT03834935
Start Date
March 1 2019
End Date
April 1 2021
Last Update
February 11 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Saint Joseph University
Beirut, Lebanon, 166830